China Vows to End Commercial Ivory Trade

Conservationists declare victory as the country agrees to crack down on domestic ivory sales, which have contributed to the near-extinction of elephant species.

By | January 4, 2017

PIXABAY, SPONCHIAChina will enforce a new ban on commercial ivory, officials announced on December 30. The ban is set to go into effect by the end of 2017, The New York Times reported, and could cripple the efforts of elephant poachers in Africa, who sell most of their wares to China. “Certainly closing down domestic ivory in China will have a dramatic impact,” John Robinson of the Wildlife Conservation Society told NPR’s The Two-Way. “The Chinese market is the largest ivory market in the world.”

The World Wildlife Foundation estimates that 20,000 elephants are poached each year in Africa, most due to Chinese demand for ivory, the International Business Times reported. Skilled Chinese artisans typically carve the ivory into ornate patterns that can sell for thousands of dollars. China’s current stockpile of legal ivory is estimated to be worth roughly $150 million, The New York Times reported.

Although new ivory has been banned internationally since 1989, prior legislation has done little to slow the lucrative ivory market in China. Since the ban did not technically prohibit ivory taken before 1989, some unscrupulous dealers had exploited this loophole to pass off new ivory as old, pre-ban samples.

Whether China’s promise will reduce  illegal ivory trade remains to be seen, but in the meantime, conservationists are optimistic. “It’s a game changer,” Elly Pepper of the Natural Resources Defense Council told NPR. “[It] could be the pivotal turning point that brings elephants back from the brink of extinction.”

Add a Comment

Avatar of: You



Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Popular Now

  1. UC Berkeley Receives CRISPR Patent in Europe
    Daily News UC Berkeley Receives CRISPR Patent in Europe

    The European Patent Office will grant patent rights over the use of CRISPR in all cell types to a University of California team, contrasting with a recent decision in the U.S.

  2. DNA Replication Errors Contribute to Cancer Risk
  3. Should Healthy People Have Their Exomes Sequenced?
    Daily News Should Healthy People Have Their Exomes Sequenced?

    With its announced launch of a whole-exome sequencing service for apparently healthy individuals, Ambry Genetics is the latest company to enter this growing market. But whether these services are useful for most people remains up for debate.  

  4. Rethinking a Cancer Drug Target
    Daily News Rethinking a Cancer Drug Target

    The results of a CRISPR-Cas9 study suggest that MELK—a protein thought to play a critical role in cancer—is not necessary for cancer cell survival.

Business Birmingham